(MedPage Today) — A peptide vaccine targeting KRAS mutations in pancreatic cancer showed preliminary evidence of activity in a small study of high-risk patients.
The vaccine elicited KRAS-specific T-cell responses in 18 of 20 patients with mutations…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
